Back to Search
Start Over
Therapeutic Benefits of Short-Arm Human Centrifugation in Multiple Sclerosis-A New Approach.
- Source :
-
Frontiers in neurology [Front Neurol] 2022 Jan 04; Vol. 12, pp. 746832. Date of Electronic Publication: 2022 Jan 04 (Print Publication: 2021). - Publication Year :
- 2022
-
Abstract
- Short-arm human centrifugation (SAHC) is proposed as a robust countermeasure to treat deconditioning and prevent progressive disability in a case of secondary progressive multiple sclerosis. Based on long-term physiological knowledge derived from space medicine and missions, artificial gravity training seems to be a promising physical rehabilitation approach toward the prevention of musculoskeletal decrement due to confinement and inactivity. So, the present study proposes a novel infrastructure based on SAHC to investigate the hypothesis that artificial gravity ameliorates the degree of disability. The patient was submitted to a 4-week training programme including three weekly sessions of 30 min of intermittent centrifugation at 1.5-2 g . During sessions, cardiovascular, muscle oxygen saturation (SmO <subscript>2</subscript> ) and electroencephalographic (EEG) responses were monitored, whereas neurological and physical performance tests were carried out before and after the intervention. Cardiovascular parameters improved in a way reminiscent of adaptations to aerobic exercise. SmO <subscript>2</subscript> decreased during sessions concomitant with increased g load, and, as training progressed, SmO <subscript>2</subscript> of the suffering limb dropped, both effects suggesting increased oxygen use, similar to that seen during hard exercise. EEG showed increased slow and decreased fast brain waves, with brain reorganization/plasticity evidenced through functional connectivity alterations. Multiple-sclerosis-related disability and balance capacity also improved. Overall, this study provides novel evidence supporting SAHC as a promising therapeutic strategy in multiple sclerosis, based on mechanical loading, thereby setting the basis for future randomized controlled trials.<br />Competing Interests: JV is the director and founder of the ThirdAge company. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Kourtidou-Papadeli, Frantzidis, Bakirtzis, Petridou, Gilou, Karkala, Machairas, Kantouris, Nday, Dermitzakis, Bakas, Mougios, Bamidis and Vernikos.)
Details
- Language :
- English
- ISSN :
- 1664-2295
- Volume :
- 12
- Database :
- MEDLINE
- Journal :
- Frontiers in neurology
- Publication Type :
- Academic Journal
- Accession number :
- 35058870
- Full Text :
- https://doi.org/10.3389/fneur.2021.746832